FibroGen Inc

0.7600+0.0199+2.69%Vol 4.47M1Y Perf -94.63%
Oct 4th, 2023 15:23 DELAYED
BID0.7593 ASK0.7607
Open0.7800 Previous Close0.7401
Pre-Market0.80 After-Market-
 0.06 7.92%  - -
Target Price
17.60 
Analyst Rating
Moderate Sell 3.60
Potential %
2.22K 
Finscreener Ranking
     41.14
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     32.21
Insiders Value % 3/6/12 mo.
-/-/-62 
Growth Ranking
★+     41.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-62 
Income Ranking
 —    -
Price Range Ratio 52W %
0.24 
Earnings Rating
Sell
Market Cap74.64M 
Earnings Date
6th Nov 2023
Alpha-0.04 Standard Deviation0.21
Beta0.57 

Today's Price Range

0.69200.7900

52W Range

0.701025.69

5 Year PE Ratio Range

-31.40-26.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-22.87%
1 Month
-30.18%
3 Months
-73.57%
6 Months
-96.06%
1 Year
-94.63%
3 Years
-98.21%
5 Years
-98.72%
10 Years
-

TickerPriceChg.Chg.%
FGEN0.76000.01992.69
AAPL173.711.31000.76
GOOG136.242.94002.21
MSFT319.235.84001.86
XOM111.11-4.7200-4.07
WFC38.900.23000.59
JNJ155.410.07000.05
FB196.640.99000.51
GE108.831.07000.99
JPM142.900.19480.14
Financial StrengthValueIndustryS&P 500US Markets
1.70
1.90
0.76
3.52
592.20
Leverage Ratio 6.70
ProfitabilityValueIndustryS&P 500US Markets
82.10
-295.70
-287.20
-217.90
-83.64
RevenueValueIndustryS&P 500US Markets
106.37M
1.13
1.68
8.28
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.72-0.659.72
Q01 2023-0.76-0.81-6.58
Q04 2022-0.95-0.7026.32
Q03 2022-0.83-0.98-18.07
Q02 2022-0.94-0.7817.02
Q01 2022-0.84-0.6819.05
Q04 2021-0.68-1.45-113.24
Q03 20210.090.54500.00
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.68-11.48Negative
12/2023 QR-0.3439.29Positive
12/2023 FY-2.474.63Positive
12/2024 FY-0.8056.04Positive
Next Report Date6th Nov 2023
Estimated EPS Next Report-0.68
Estimates Count3
EPS Growth Next 5 Years %33.80
Volume Overview
Volume4.47M
Shares Outstanding98.21K
Shares Float95.86M
Trades Count8.82K
Dollar Volume3.29M
Avg. Volume5.64M
Avg. Weekly Volume6.04M
Avg. Monthly Volume6.47M
Avg. Quarterly Volume4.40M

FibroGen Inc (NASDAQ: FGEN) stock closed at 0.7401 per share at the end of the most recent trading day (a -8.63% change compared to the prior day closing price) with a volume of 5.75M shares and market capitalization of 74.64M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.

The one-year performance of FibroGen Inc stock is -94.63%, while year-to-date (YTD) performance is -95.38%. FGEN stock has a five-year performance of -98.72%. Its 52-week range is between 0.701 and 25.69, which gives FGEN stock a 52-week price range ratio of 0.24%

FibroGen Inc currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 70.68, a price-to-sale (PS) ratio of 17.58, a price to cashflow ratio of 12.50, a PEG ratio of -0.15, a ROA of -44.18%, a ROC of -132.33% and a ROE of -172.16%. The company’s profit margin is -83.64%, its EBITDA margin is -287.20%, and its revenue ttm is $106.37 Million , which makes it $1.13 revenue per share.

Of the last four earnings reports from FibroGen Inc, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. FibroGen Inc’s next earnings report date is 06th Nov 2023.

The consensus rating of Wall Street analysts for FibroGen Inc is Moderate Sell (3.6), with a target price of $17.6, which is +2 216.70% compared to the current price. The earnings rating for FibroGen Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

FibroGen Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 22.26, ATR14 : 0.12, CCI20 : -129.00, Chaikin Money Flow : -0.11, MACD : -0.19, Money Flow Index : 28.34, ROC : -14.25, RSI : 31.17, STOCH (14,3) : 13.11, STOCH RSI : 0.00, UO : 42.19, Williams %R : -86.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Aoife Brennan (Sold 4 733 shares of value $81 367 ), Blaug Suzanne (Sold 17 040 shares of value $293 142 ), Brennan Aoife (Sold 4 733 shares of value $81 367 ), Christine Chung (Sold 9 185 shares of value $164 760 ), Chung Christine (Sold 51 161 shares of value $938 797 ), Conterno Enrique (Sold 88 054 shares of value $1 772 606 ), Conterno Enrique A (Sold 8 897 shares of value $151 583 ), Cravatt Benjamin (Sold 7 888 shares of value $135 434 ), EDWARDS JEFFREY L (Sold 7 889 shares of value $135 622 ), Eisner Mark (Sold 34 136 shares of value $669 664 ), Enrique A. Conterno (Sold 21 027 shares of value $424 308 ), Graham Juan (Sold 11 231 shares of value $218 033 ), Henderson Jeffrey William (Sold 7 000 shares of value $122 185 ), Ho Maykin (Sold 8 520 shares of value $148 591 ), Jeffrey W. Henderson (Sold 2 000 shares of value $2 060 ), Juan Graham (Sold 7 929 shares of value $117 536 ), Mark Eisner (Sold 10 369 shares of value $198 433 ), Schoeneck James (Sold 7 100 shares of value $128 013 ), Schoeneck James A (Sold 7 100 shares of value $127 987 ), Thane Wettig (Sold 734 shares of value $11 597 ), Wettig Thane (Sold 19 146 shares of value $377 396 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
4 (66.67 %)
6 (85.71 %)
Moderate Sell
1 (20.00 %)
1 (16.67 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
1 (16.67 %)
1 (14.29 %)
Summary RatingModerate Sell
3.60
Hold
3.50
Hold
3.29

FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

CEO: Enrique A. Conterno

Telephone: +1 415 978-1200

Address: 409 Illinois Street, San Francisco 94158, CA, US

Number of employees: 531

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

 

News

Stocktwits